Hepatocellular Carcinoma in the Setting of HBV Infection: Risk Assessment, Screening, and Surveillance

Download this PDF guide outlining key information on HCC risk assessment, screening, and surveillance in the setting of Hepatitis B infection.
Robert S. Brown, Jr., MD, MPH
Format: Adobe Acrobat (.pdf)
File Size: 88 KB
Released: February 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Dr. Takeshi Saito on increasing detection of HBV/HDV coinfection, especially among HBsAg-positive persons, examples from Mongolian population in California from Clinical Care Options (CCO)

person default Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 20, 2021 Expired: August 19, 2022

Clinical Care Options (CCO) expert commentary on optimal timing for MTCT prophylaxis in pregnant women with chronic HBV

Joseph Ahn, MD, MS, MBA Released: July 13, 2021

Download free slides reviewing key data and AASLD guidance on managing HBV infection during pregnancy

Joseph Ahn, MD, MS, MBA Released: July 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue